NEW YORK stock is up by 1.67% to $93.39 in afternoon trading on Friday, even
though the biopharmaceutical company's share of new hepatitis-C patients
fell compared to previous weeks.
The company's share of new patients declined by 1.6% from last week, according to Citigroup (C), Barron's reports.
New patient starts are tracking 0.3% lower than the prior quarter, while total scripts are tracking roughly 6% lower than last quarter, the firm continued. This translates to 2016 first quarter sales of $2.22 billion, which is below analysts' estimates for $2.46 billion.
Gilead's hepatitis C franchise is at 93% share, Citigroup adds.
Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.
Gilead's strengths such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and good cash flow from operations outweigh the fact that the company has had lackluster performance in the stock itself.
You can view the full analysis from the report here: GILD
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.
The company's share of new patients declined by 1.6% from last week, according to Citigroup (C), Barron's reports.
New patient starts are tracking 0.3% lower than the prior quarter, while total scripts are tracking roughly 6% lower than last quarter, the firm continued. This translates to 2016 first quarter sales of $2.22 billion, which is below analysts' estimates for $2.46 billion.
Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.
Gilead's strengths such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and good cash flow from operations outweigh the fact that the company has had lackluster performance in the stock itself.
You can view the full analysis from the report here: GILD
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.